GPCR vs RVMD vs KYMR vs AMGN vs CRL

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Structure Therapeutics Inc. (GPCR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Amgen Inc.

is actually cheaper at 14. 7x.

Over the past 5 years, Revolution Medicines, Inc.

(RVMD) delivered a total return of +382. 1%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: RVMD returned +393. 1% versus GPCR's +50. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 153% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Structure Therapeutics Inc. (GPCR) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amgen Inc.

(AMGN) trades at 14. 7x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GPCR: 193. 1% to $114. 75.

In this comparison, AMGN (2.

9% yield) pays a dividend. GPCR, RVMD, KYMR, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +156. 4%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN pays a dividend while GPCR, RVMD, KYMR, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.